Notice of AGM

RNS Number : 0599Q

Redx Pharma plc

15 February 2023

 

REDX PHARMA PLC

("Redx" or "the Company")

Notice of Annual General Meeting

Alderley Park, 15 February 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease , today announces that its Annual General Meeting will be held at 11am on 14 March 2023 at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ.

Following the announcement of preliminary results for the financial year ended 30 September 2022 on 20 December 2022, the Company announces that the Annual Report and Accounts and notice of Annual General Meeting have now been posted to shareholders. The Annual Report and Accounts and notice of Annual General Meeting are also available to view on Redx's website at  www.redxpharma.com .

Shareholders are strongly encouraged to vote by proxy, appointing the Chair of the meeting, using the form of proxy distributed with the notice of meeting, to ensure their vote counts. The form of proxy is also available in the investor resources section of the Company's website:  www.redxpharma.com

Completed proxies should be returned to:

Equiniti

Aspect House

Spencer Road

Lancing

BN99 6DA

and must be received by 11am on 10 March 2023 to be valid.

For further information, please contact:
Redx Pharma Plc   UK Headquarters   Caitlin Pearson, Head of Communications  [e-mail]   Lisa Anson, Chief Executive Officer	T: [phone]
US Office  Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)	T: [phone]
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)	T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting	T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor,  and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/  

 

END

 

 

NOAGPURWPUPWGQA